{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:26:48Z","timestamp":1792981608795,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19-AI123862"],"award-info":[{"award-number":["U19-AI123862"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21-AI126582"],"award-info":[{"award-number":["R21-AI126582"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI132213"],"award-info":[{"award-number":["R01-AI132213"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["ERC-AdG-2014-671231-HEPCIR"],"award-info":[{"award-number":["ERC-AdG-2014-671231-HEPCIR"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["H2020-2015-667273-HEP-CAR"],"award-info":[{"award-number":["H2020-2015-667273-HEP-CAR"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004795","name":"Institut Universitaire de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.antiviral.2018.12.018","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T20:35:10Z","timestamp":1546115710000},"page":"136-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection"],"prefix":"10.1016","volume":"162","author":[{"given":"Laurent","family":"Mailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wrensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-2267","authenticated-orcid":false,"given":"Laura","family":"Heydmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fauvelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Brignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam B.","family":"Zeisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pessaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-yong","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fuerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.H.","family":"Foung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.12.018_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.antiviral.2018.12.018_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12916-017-0815-7","article-title":"Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals","volume":"15","author":"Baumert","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.antiviral.2018.12.018_bib3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-016-9724-7","article-title":"Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals","volume":"10","author":"Colpitts","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2018.12.018_bib4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1021\/acsinfecdis.7b00091","article-title":"Entry inhibitors: a perspective for prevention of hepatitis C virus infection in organ transplantation","volume":"3","author":"Colpitts","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.12.018_bib5","first-page":"736","article-title":"Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape","volume":"67","author":"Colpitts","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2018.12.018_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284818759483","article-title":"Host-targeting therapies for hepatitis C virus infection: current developments and future applications","volume":"11","author":"Crouchet","year":"2018","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.12.018_bib7","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/hep.28428","article-title":"Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge","volume":"63","author":"Desombere","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2017.10.015","article-title":"A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo","volume":"148","author":"Desombere","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.12.018_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib10","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.20090766","article-title":"Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation","volume":"207","author":"Fafi-Kremer","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2018.12.018_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.gastro.2012.04.006","article-title":"Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies","volume":"143","author":"Fofana","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib12","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1128\/JVI.03676-14","article-title":"Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model","volume":"89","author":"Fukasawa","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.018_bib40","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.87.24.9524","article-title":"Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis","volume":"87","author":"Kato","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.12.018_bib14","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/hep.28850","article-title":"Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice","volume":"64","author":"Keck","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.12.018_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.antiviral.2017.01.001","article-title":"Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy","volume":"139","author":"Khera","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.12.018_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2012.02.018","article-title":"Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice","volume":"57","author":"Lacek","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.12.018_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.12.018_bib41","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/ajg.2017.157","article-title":"Spanish group for the study of the use of direct-acting drugs hepatitis C collaborating group. interferon-free therapy in elderly patients with advanced liver disease","volume":"112","author":"Lens","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.12.018_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.12.018_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.3179","article-title":"Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody","volume":"33","author":"Mailly","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.12.018_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/hep.24171","article-title":"In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus","volume":"53","author":"Meuleman","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.24692","article-title":"A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo","volume":"55","author":"Meuleman","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.22547","article-title":"Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo","volume":"48","author":"Meuleman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/lt.24344","article-title":"Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate","volume":"22","author":"O'Shea","year":"2016","journal-title":"Liver Transplant."},{"key":"10.1016\/j.antiviral.2018.12.018_bib26","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3237","article-title":"Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals","author":"Palanisamy","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.12.018_bib27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJM199108153250702","article-title":"Transmission of hepatitis C virus by organ transplantation","volume":"325","author":"Pereira","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.12.018_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.antiviral.2018.12.018_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.12.018_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02258-17","article-title":"Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model","volume":"92","author":"Shimizu","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.018_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jvh.12632","article-title":"Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: a proof-of-concept study","volume":"24","author":"Smith","year":"2017","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2018.12.018_bib32","series-title":"United Network for Organ Sharing - Annual Report 2016","year":"2016"},{"key":"10.1016\/j.antiviral.2018.12.018_bib33","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/gutjnl-2014-309045","article-title":"Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice","volume":"65","author":"Vercauteren","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2018.12.018_bib34","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/hep.27196","article-title":"Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents","volume":"60","author":"Vercauteren","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.12.018_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.scr.2014.08.006","article-title":"Extensive double humanization of both liver and hematopoiesis in FRGN mice","volume":"13","author":"Wilson","year":"2014","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.antiviral.2018.12.018_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","article-title":"Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C","volume":"64","author":"Xiao","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2018.12.018_bib36","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0140-6736(17)30043-0","article-title":"Clinical development of hepatitis C virus host-targeting agents","volume":"389","author":"Zeisel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.12.018_bib37","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.3390\/v7112898","article-title":"Host-targeting agents to prevent and cure hepatitis C virus infection","volume":"7","author":"Zeisel","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.12.018_bib38","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","article-title":"Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses","volume":"10","author":"Zhao","year":"2004","journal-title":"Clin. Cancer Res. Offic. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.antiviral.2018.12.018_bib39","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged <\/=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR. Morb. Mortal. Wkl. Rep."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:19Z","timestamp":1759062499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":40,"alternative-id":["S0166354218305114"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.018","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}